Facebook link Linked In link You Tube link

Education Faculty Biographies


Shiv Pillai, MD, PhD
Massachusetts General Hospital
Dr. Pillai completed his medical studies at the Christian Medical College, Vellore, in south India, and went on to obtain a PhD in Biochemistry from Calcutta University. He was an investigator at the Kothari Center for Gastroenterology in Calcutta until 1983, and was a postdoctoral fellow at the Whitehead Institute in Cambridge from 1984-1988. Since 1988 he has been a faculty member at the Cancer Center and the Department of Medicine at Massachusetts General Hospital and Harvard Medical School. He discovered surrogate light chains and the pre-B receptor as a post-doctoral fellow, and his laboratory at MGH has been largely focused on studies on B lymphocyte development, signaling, tolerance, and more recently on the genetic basis of human autoimmune disorders. Dr. Pillai is on the Editorial Boards of the Journal of Clinical Investigation and the Journal of Immunology ,is the director of immunology courses taught at Harvard College and Harvard Medical School, and teaches in a number of other courses at both institutions. He has received numerous teaching awards, including the Irving London Award, is the author of Lymphocyte Development, and is co-author with Abul Abbas and Andrew Lichtman of Cellular and Molecular Immunology.

Kenneth Rock, MD
University of Massachusetts
Dr. Kenneth Rock is professor and chairman of Pathology at UMass Medical School. He is an ISI highly cited researcher in the field of Immunology and has published >190 papers. One area of his research is on antigen presentation. His laboratory established many of the key underlying mechanisms in antigen presentation including the role of the proteasome, cytosolic aminopeptidases, and ERAP1 in MHC class I presentation, the cellular and cell biological basis of cross presentation, and the underlying mechanisms of antigen presentation in T-B cell interactions. Another area of his research is on how cell death and danger signals influence immune responses and more broadly how sterile stimuli stimulate innate immunity and inflammation. In this subject area his laboratory established the molecular identity of the first endogenous danger signal (MSU) and a key common pathway, involving IL-1 and inflammasomes, through which many structurally distinct stimuli cause sterile inflammation.

Abul Abbas, MD
University of California, San Francisco
Dr. Abbas received his MD from the All India Institute of Medical Sciences in India, completed training in Pathology at the Brigham & Women's Hospital and Harvard and joined the faculty at Harvard Medical School and the Brigham and Women's Hospital, where he rose to become Professor of Pathology and Head of the Immunology Research Division. In 1999, he moved to the University of California-San Francisco as Professor and Chairman of the Department of Pathology. Dr. Abbas has received several teaching awards at Harvard and UCSF, and numerous honors, including election to the Institute of Medicine of the National Academy of Sciences and as a Fellow of the American Academy of Arts and Sciences. He oversees an NIH funded laboratory in Immunology, with a focus on the control of immune responses, self tolerance and autoimmunity. He has published more than 190 peer reviewed papers and invited reviews, and is an author of two widely used textbooks of Immunology, as well as Robbins & Cotran's Pathologic Basis of Disease.

Andrew Lichtman, MD, PhD
Brigham & Women's Hospital
Dr. Lichtman received an A.B degree of Bowdoin College in 1974, and MD and PhD (Biophysics) degrees from the University of Rochester School of Medicine in 1981. He trained in anatomic pathology and completed a post-doctoral research fellowship at the Brigham and Women's Hospital between 1982-1985. He is a diplomat of the American Board of Pathology, and currently holds the position of Professor of Pathology at Brigham and Women's Hospital and Harvard Medical School. He has directed a continuously N.I.H. -funded research laboratory for over 25 years. His current research focuses on T cell-mediated courses at Harvard Medical School (HMS), and is a coauthor of two widely used text books of immunology. He has received numerous teaching awards at HMS, and is the recipient of the 2014 Robbins Distinguished Educator Award of the American Society of Investigative Pathology. He has taught in postgraduate Immunology courses worldwide. He is a past Education Chair and current Publications Committee Chair of the Federation of Clinical Immunology Societies (FOCIS).

Lewis Lanier, PhD
University of California, San Francisco
Lewis L. Lanier is an American Cancer Society Professor, a Professor and Chairman of the Department of Microbiology and Immunology, and Professor of the Cancer Research Institute at the University of California San Francisco and Co-Leader of the Cancer, Immunity, and Microenvironment Program of the UCSF Helen Diller Comprehensive Cancer Center. Dr. Lanier received his Ph.D. in Microbiology and Immunology from the University of North Carolina – Chapel Hill. After postdoctoral studies, first at the Lineberg Cancer Center at the UNC – Chapel Hill and then as a Damon Runyon – Walter Winchell Cancer Research Fellow at the University of New Mexico, he joined the Research & Development Department at the Becton Dickinson Monoclonal Center in Mountain View, California, advancing to Associate Director of Research and was a Becton Dickinson Research Fellow. In 1990, he joined the DNAX Research Institute of Molecular and Cellular Biology in Palo Alto, California, where he advanced to Director of Immunobiology. In 1999, Dr. Lanier joined the faculty of UCSF School of Medicine in San Francisco. His research group studies Natural Killer (NK) cells, which recognize and eliminate cells that have become transformed or infected by viruses. In recognition of his scientific contributions he was awarded the William B. Coley Award for Distinguished Research in Basic Tumor Immunology from the Cancer Research Institute in New York in 2002, in 2005 was given the Rose Payne Award for contributions to the field of Immunogenetics by the American Society for Histocompatibility and Immunogenetics, in 2010 was elected to the US National Academy of Sciences, and in 2011 was named a Fellow of the American Academy of Microbiology by the American Society for Microbiology and elected to the American Academy of Arts and Sciences. He was awarded the 2001 Distinguished Service Award from the American Association of Immunologists and served as President of the American Association of Immunologists (2006-2007). He has published more than 400 scientific articles and is a Senior Editor of the Journal of Experimental Medicine, and also has served on the editorial boards of the Journal of Immunology, Annual Review of Immunology, Immunological Reviews, Tissue Antigens, Human Immunology, Immunogenetics, and Immunity. Dr. Lanier serves on the Scientific Advisory Board of several pharma and biotech companies and research institutes.

Catherine Wu, MD
Dana Farber Cancer Institute
Catherine J. Wu, MD is an Associate Professor in Medicine at the Dana-Farber Cancer Institute, Boston. She received her M.D. from Stanford University School of Medicine and completed her clinical training in Internal Medicine and Hematology-Oncology at the Brigham and Women's Hospital and Dana-Farber Cancer Institute in Boston, MA. She joined the staff at the Dana-Farber Cancer Institute in 2000. At DFCI, she has initiated an integrated program of research and clinical activities that focuses on dissecting the underlying mechanisms of pathobiology of chronic lymphocytic leukemia (CLL) as a means to more rationally generate effective therapies, including immune-based treatments, for this common adult leukemia. She has been principal investigator of several center-initiated clinical trials, including an ongoing study that examines the effects of a personal whole tumor cell-based vaccine on outcomes following allogeneic hematopoietic stem cell transplant for the treatment of CLL. A major priority of her studies is the identification of tumor-specific antigens that would allow effective tumor targeting without collateral toxicity. She has been using exome and transcriptome sequencing technologies to identify unique mutated leukemia antigens that arise from individual-specific genetic alterations within a tumor and that could be potentially targeted immunologically, thus paving the way for developing personalized tumor vaccines. Through large-scale genome analysis of chronic lymphocytic leukemia, her laboratory has further discovered key mutated genes and pathways involved in CLL. Other ongoing studies in her laboratory focus on systematically analyzing tumor genotype – phenotype relationships, understanding CLL tumor heterogeneity; and mechanistically dissecting the impact of novel CLL driver genes.

Jane Buckner, MD
Benaroya Research Institute
Dr. Buckner attended Johns Hopkins School of Medicine. She completed her medical and postdoctoral training in rheumatology at the University of Washington. Since 1999 Dr. Buckner has been an investigator at the Benaroya Research Institute, and she is now the Director of the Translational Research Program at BRI and Associate Director of the Institute. Her laboratory is focused on identifying the underlying mechanisms by which regulation of the adaptive immune response fails in the setting of human autoimmunity. Currently her group is using both genetic and cell based approaches to examining these questions in type 1 diabetes, multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosis.

Richard Blumberg, MD
Brigham & Women's Hospital
Dr. Richard S. Blumberg trained in internal medicine (The New York Hospital, 1982), infectious diseases (Massachusetts General Hospital, 1986) and gastroenterology & hepatology (Brigham & Women's Hospital, 1989). He is currently Senior Physician in Medicine and Gastroenterology at Brigham and Women's Hospital (BWH) where he leads the Division of Gastroenterology, Hepatology and Endoscopy, is Professor of Medicine at Harvard Medical School and co-Director of the Harvard Digestive Diseases Center. In addition, Dr. Blumberg serves on the Executive Advisory Committee of the Department of Medicine and is the incoming Chair of the Biomedical Research Institute at BWH. He has served as a member of the Immunology Sciences Study Section of NIAID, a member on the National Commission of Digestive Diseases of the NIDDK, scientific consultant to the Human Microbiome Project (NHGRI), a member of the Vaccine Branch External Advisory Board (NCI), Chair of the External Scientific Consultants for the Intestinal Stem Cell Consortium Initiative (NIDDK) and is currently on the Board of Scientific Councilors (NIAID). He served as the Chair of the National Scientific Advisory Committee of the Crohn's & Colitis of America (2002-2005) and President of the Society for Mucosal Immunology (2007-2009). Dr. Blumberg is an elected member of the American Association of Clinical Investigation and the Association of American Physicians and the recipient of a MERIT Award from the NIH (2005), the William Beaumont Prize from the American Gastroenterological Association (2012) and the Distinguished Scientific Achievement Award from the Crohn's and Colitis Foundation of America (2012). He is an NIH-funded investigator whose research program focuses on mucosal immunology and was Scientific Founder, Syntonix Pharmaceuticals that developed long-acting therapeutic agents successful in the treatment of chronic diseases.

Steven Holland, MD
National Institutes of Health, National Institute of Allergy and Infectious Diseases
Dr. Steven M. Holland received his BA from St. John's College in Annapolis, Maryland, in 1979 and his MD from Johns Hopkins University School of Medicine in 1983. He stayed at Hopkins as an intern, resident, and chief resident in internal medicine, followed by a fellowship in infectious diseases. He came to the NIH in 1989 to study the molecular biology of HIV, and in 1991 moved to the study phagocytes and phagocyte immunodeficiencies. In 2004 he became Chief, Laboratory of Clinical Infectious Diseases, NIAID. In 2011 he was named the Deputy Director for Intramural Clinical Research, NIH. His work centers on understanding the pathophysiology and treatment of infections in patients with congenital and acquired immune defects affecting phagocytes. Areas of interest include mycobacterial infections (interferon gamma/IL-12 pathway defects, anticytokine autoantibodies, GATA2), hyper IgE syndrome (STAT3, DOCK8), and chronic granulomatous disease.

Jonathan Maltzman, MD, PhD
University of Pennsylvania
Dr. Maltzman is an Assistant Professor in the Renal-Electrolyte and Hypertension Division, Department of Medicine at the University of Pennsylvania. He received his undergraduate degree in Biology from the Massachusetts Institute of Technology, and his M.D. and Ph.D. degrees from the University of Pennsylvania School of Medicine. He completed his residency in Internal Medicine at the University of Chicago followed by his fellowship in Nephrology and post-doctoral work at the University of Pennsylvania. Dr Maltzman's academic interest is focused on understanding immune responses in transplantation and he has clinical duties caring for kidney transplant patients. His laboratory has been a pioneer in the use of conditional gene expression to study signal transduction in memory T lymphocytes and also has ongoing projects investigating regulatory T cells as well as the interplay between infection and transplantation. Dr Maltzman is a past recipient of the John Merrill Award from the American Society of Nephrology and American Society of Transplantation as well as the AST Basic Science Career Development Award. Dr Maltzman was inducted into the American Society of Clinical Investigation in 2012.

Mark Anderson, MD, PhD
University of California, San Francisco
Dr. Anderson earned his MD and PhD at the University of Chicago in 1994 and completed his residency at the University of Minnesota. He was the chief resident at the University of Minnesota from 1997-1998, and then completed his fellowship in endocrinology at Massachusetts General Hospital. He achieved his Board Certification in Endocrinology and Metabolism in 2001, and renewed it in 2012. He is currently a Professor at the University of California, San Francisco School of Medicine.

Thorsten Mempel, MD, PhD
Massachusetts General Hospital
Thorsten Mempel, MD, PhD, is the Principal Investigator at the Centre for Immunology and Inflammatory Diseases at Massachusetts General Hospital. He is also an Assitant Professor of medicine at Harvard Medical School.
The Mempel Labratory investigates cell migration and intercellular communction in the adaptive immune system through direct dynamic in vivo visualization of immune cell behavior using multiphoton intravital microscopy in mice.